Peptide vaccine and peptide vaccine composition for cranial nerve disease

Abstract

A peptide vaccine for a cranial nerve disease is disclosed, said peptide vaccine comprising a peptide capable of inducing a cytotoxic T cell (CTL) to a cell expressing vascular endothelial growth factor receptor (VEGFR)-1 or a peptide capable of inducing a CTL to a cell expressing VEGFR-2.

Description

technical field [0001] The present invention relates to peptide vaccines and peptide vaccine compositions against cranial nerve diseases. This application claims priority based on Japanese Patent Application No. 2017-100361 for which it applied in Japan on May 19, 2017, and uses the content here. Background technique [0002] Neurofibromatosis type II (NF2), brain tumors, cerebrovascular diseases, autoimmune diseases, ophthalmic diseases, etc. are included in cranial nerve diseases. For example, NF2 is an autosomal dominant genetic disease caused by gene abnormality of the tumor suppressor merlin present in the long arm of chromosome 22, 22q12. The diagnosis of NF2 is determined by the occurrence of acoustic nerve tumors (precisely, vestibular schwannomas) on the left and right sides. Many tumors occur in NF2. Specifically, schwannomas occur in cranial nerves, spinal nerves, and peripheral nerves, and meningiomas, ependymomas, gliomas, and the like occur in the intracrani...

AI Technical Summary

Problems solved by technology

However, since the schwannomas of NF2 patients are hemorrhagic tumors, there is a high possibility that peripheral nerves will be damaged during surgery, and surgery cannot be performed aggressively especially for multiple tumors

In addition, although radiotherapy is also effective for smaller tumors, long-term control is often difficult, and there is also a risk of malignant transformation

Images